Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Pfizer in Acquisition of BioRexis

February 1, 2007

NEW YORK, NY, February 1, 2007 — Covington & Burling LLP advised Pfizer in the acquisition of BioRexis, a privately held biopharmaceutical company. The transaction is expected to close in the first or second quarter of 2007. The financial terms of the transaction were not disclosed.

BioRexis is developing long-acting GLP-1 receptor agonists for the potential treatment of patients with type 2 diabetes. Early studies with these compounds support their potential to advance new treatment options for the disease.

The Covington corporate team included partner Scott Smith and associates Andrew Muratore, Michelle Garcia, and Michael Tzartzouras. The New York and Washington based team included Corinne Goldstein (environmental), Scott Cunningham (FDA), Michael Francese and Kendra Roberson (benefits), Robert Heller (tax), and Natalie Derzko (intellectual property).

Share this article: